Cracking the auditory genetic code: Part II. Syndromic hereditary hearing impairment

American Journal of Otology

Volumn 21, Issue 3, 2000, Pages 437-451

  Tseng, Charles J ^a,b   Lalwani, Anil K ^a,b  

^a Epstein Laboratories   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hereditary hearing impairment; Molecular genetics; Syndromic hearing impairment

Indexed keywords

ALPORT SYNDROME; BRANCHIOOTORENAL SYNDROME; CROUZON SYNDROME; DATA BASE; GENETIC CODE; HEARING IMPAIRMENT; HUMAN; INTERNET; MANDIBULOFACIAL DYSOSTOSIS; MEDICAL INFORMATION; MOLECULAR GENETICS; NEUROFIBROMATOSIS; NORRIE DISEASE; PENDRED SYNDROME; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION; USHER SYNDROME; WAARDENBURG SYNDROME;

EID: 0034068316     PISSN: 01929763     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0196-0709(00)80058-7     Document Type: Review

References (146)

1. Online London Dysmorphology Database. London: Oxford University Press, 1999. URL: http://dhmhd.mdx.ac.uk/LDDB/ lddb.html
2. Lalwani AK, Castelein CM. Cracking the auditory genetic code: nonsyndromic hereditary hearing impairment. Am J Otol 1999; 29:115-32.
3. Waardenburg PHJ. A new syndrome combining developmental anomalies of the eyelids, eyebrows, and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet 1951;3:195-253.
4. Morell R, Friedman TB, Asher JH Jr, et al. The incidence of deafness is nonrandomly distributed among families segregating for Waardenburg syndrome type 1 (WS1). J Med Genet 1997;34: 447-52.
5. Klein D. Albinisme partiel (leucisme) avec surdi-mutite, blepharophimosis et dysplasie myo-osteo-articulaire. Helv Paediatr Acta 1950;5:38-58.
6. Shah DN, Dalal SJ, Desai MP, et al. White forelock, pigmentary disorder of irides, and long segment Hirschsprung disease: possible variant of Waardenburg syndrome. J Pediatr 1981;99: 432-5.
7. Tassabehji M, Read AP, Newton VE, et al. Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature 1992;355:635-6.
8. Tassabehji M, Newton VE, Leverton K, et al. PAX3 gene structure and mutations: close analogies between Waardenburg syndrome and the Splotch mouse. Hum Molec Genet 1994, 3:7:1069-74.
9. Tassabehji M, Newton VE, Read AP. Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 1994;8:251-5.
10. Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 1998;18:171-3.
11. Hoth CF, Milunsky A, Lipsky N, et al. Mutations in the paired domain of the human PAX3 gene cause Klein-Waardenburg syndrome (WS-III) as well as Waardenburg syndrome type I (WS-I). Am J Hum Genet 1993;52:455-62.
12. Edery P, Attie T, Amiel J, et al. Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 1996;12:442-4.
13. Attie T, Till M, Pelet A, et al. Mutation of the endothelin-receptor B gene in Waardenburg-Hirschsprung disease. Hum Molec Genet 1995;12:2407-9.
14. Grundfast KM, San Agustin TB. Finding the genes for Waardenburg syndromes. Otolarynol Clin North Am 1992;25:935-51.
15. Read AP, Newton VE. Waardenburg syndrome. J Med Genet 1997;34:656-65.
16. Newton VE. Waardenburg's syndrome: a comparison of biometric indices used to diagnose lateral displacement of the inner canthi. Scand Audiol 1989;18:221-3.
17. Ishikiriyama S, Tonoki H, Shibuya Y, et al. Waardenburg syndrome type I in a child with de novo inversion (2) (q35q37.2). Am J Med Genet 1989;33:505-7.
18. Epstein DJ, Vekemans M, Gros P. Splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3. Cell 1991;67:767-74.
19. Foy C, Newton VE, Wellesley D, et al. Assignment of the locus for Waardenburg syndrome type I to human chromosome 2q37 and possible homology to the Splotch mouse. Am J Hum Genet 1990;46:1017-23.
20. Baldwin CT, Hoth CF, Amos JA, et al. An exonic mutation in the HuP2 paired domain gene causes Waardenburg syndrome. Nature 1992;355:637-8.
21. Chalepakis G, Stoykova A, Wijnholds J, et al. Pax: gene regulators in the developing nervous system. J Neurobiol 1993;24: 1367-84.
22. Dahl E, Koseki H, Balling R. Pax genes and organogenesis. Bioessays 1997;19:755-65.
23. Reynolds JE, Arnos KS, Landa B, et al. Analysis of locus heterogeneity in Waardenburg syndrome types 1 and 2 using highly informative microsatellite markers. Hum Hered 1995;45:243-52.
24. Farrer LA, Arnos KS, Asher JH Jr, et al. Locus heterogeneity for Waardenburg syndrome is predictive of clinical subtypes. Am J Hum Genet 1994;55:728-37.
25. Wang C, Kim E, Attaie A, et al. A PAX3 polymorphism (T315K) in a family exhibiting Waardenburg Syndrome type 2. Molec Cell Probes 1998;12:55-7.
26. Zlotogora J, Lerer I, Bar-David S, et al. Homozygosity for Waardenburg syndrome. Am J Hum Genet 1995;56:1173-8.
27. Lalwani AK, Brister JR, Fex J, et al. Further elucidation of the genomic structure of PAX3, and identification of two different point mutations within the PAX3 homeobox that cause Waardenburg syndrome type 1 in two families. Am J Hum Genet 1995; 56:75-83.
28. Morell R, Carey ML, Lalwani AK, et al. Three mutations in the paired homeodomain of PAX3 that cause Waardenburg syndrome type 1. Hum Hered 1997;47:38-41.
29. Attaie A, Kim E, Wilcox ER, et al. A splice-site mutation affecting the paired box of PAX3 in a three generation family with Waardenburg syndrome type I (WS1). Molec Cell Probes 1997; 11:233-6.
30. DeStefano AL, Cupples LA, Arnos KS, et al. Correlation between Waardenburg syndrome phenotype and genotype in a population of individuals with identified PAX3 mutations. Hum Genet 1998; 102:499-506
31. Lalwani AK, Mhatre AN, San Agustin TB, et al. Genotype-phenotype correlations in type 1 Waardenburg syndrome. Laryngoscope 1996;106:895-902.
32. Lalwani AK, Attaie A, Randolph FT, et al. Point mutation in the MITF gene causing Waardenburg syndrome type II in a three-generation Indian family. Am J Med Genet 1998;80:406-9.
33. Yasumoto K, Yokoyama K, Shibata K, et al. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Molec Cell Biol 1994;14:8058-70.
34. Watanabe A, Takeda K, Ploplis B, et al. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat Genet 1998;18:283-6.
35. Moore SW, Johnson AG. Hirschsprung's disease: genetic and functional associations of Down's and Waardenburg syndromes. Semin Pediatr Surg 1998;7:156-61.
36. Southard-Smith EM, Kos L, Pavan WJ. Sox 10 mutation disrupts neural crest development in Dom Hirschsprung mouse model. Nat Genet 1998;18:60-4.
37. Usher CH. On the inheritance of retinitis pigmentosa, with notes of cases. R Lond Ophthalmol Hasp Rep 1914;19:130-236.
38. Rosenberg T, Haim M, Hauch AM, et al. The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. Clin Genet 1997;51:314-21.
39. Davenport SLH, Omenn GS. The heterogeneity of Usher syndrome [Abstract]. Vth International Conference on Birth Defects, Montreal, August 1977.
40. Van Camp G, Smith RJH. Hereditary hearing loss homepage. World Wide Web URL: http://dnalab-www.uia.ac.be/dnalab/hhh/
41. Weil D, Blanchard S, Kaplan J, et al. Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature 1995;374: 60-1.
42. Guilford P, Ayadi H, Blanchard S, et al. A human gene responsible for neurosensory, nonsyndromic recessive deafness is a candidate homologue of the mouse sh-1 gene. Hum Molec Genet 1994;3:989-93.
43. Liu XZ, Walsh J, Tamagawa Y, et al. Autosomal dominant non-syndromic deafness caused by a mutation in the myosin VIIA gene. Nat Genet 1997;17:268-9.
44. Hassan T. Unconventional myosins, the basis for deafness in mouse and man. Am J Hum Genet 1997;61:801-5.
45. Liu X, Udovichenko IP, Brown SD, et al. Myosin VIIa participates in opsin transport through the photoreceptor cilium. J Neurosci 1999;19:6267-74.
46. Self T, Mahony M, Fleming J, et al. Shaker-1 mutations reveal roles for myosin VIIA in both development and function of cochlear hair cells. Development 1998;125:557-66.
47. Avraham KB, Hasson T, Sobe T, et al. Characterization of unconventional MYO6, the human homologue of the gene responsible for deafness in Snell's waltzer mice. Hum Molec Genet 1997;8:1225-31.
48. Wang A, Liang Y, Fridell RA, et al. Association of unconventional myosin MYO15 mutations with human nonsyndromic deafness DFNB3. Science 1998;280:1447-51.
49. Eudy JD, Weston MD, Yao S, et al. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science 1998;280:1753-7.
50. Hmani M, Ghorbel A, Boulila-Elgaied A, et al. A novel locus for Usher syndrome type II, USH2B, maps to chromosome 3 at p23-24.2. Eur J Hum Genet 1999;7:363-7.
51. Pieke Dahl S, Kelly PM, Astuto LM, et al. Localization of USH2B to 5q14.3-q21.3 [Abstract 88]. The Molecular Biology of Hearing and Deafness Meeting, Bethesda, October 8-11, 1998.
52. Grondahl J, Mjoen S. Usher syndrome in four Norwegian counties. Clin Genet 1986;30:14-28.
53. Sankila EM, Pakarinen L, Kaariainen H, et al. Assignment of an Usher syndrome type III (USH3) gene to chromosome 3q. Hum Molec Genet 1995;4:93-8.
54. Pendred V. Deaf mutism and goitre. Lancet 1896;11:532.
55. Smith RE. Pendred's syndrome: a historical note. Guys Hosp Rep 1969:118:519-21.
56. Batsakis JG, Nishiyama RH. Deafness with sporadic goiter: Pendred's syndrome. Arch Otolaryngol 1962;76:401-6.
57. Gomez-Pan A, Evered DC, Hall R. Pituitary-thyroid function in Pendred syndrome. Br Med J 1974:2:152-3.
58. Fraser GR, Morgans ME, Trotter WR. The syndrome of sporadic goiter and congenital deafness. Quart J Med 1960;29:279-95.
59. Cremers CW, Admiraal RJ, Huygen PL, et al. Progressive hearing loss, hypoplasia of the cochlea and widened vestibular aqueducts are very common features in Pendred's syndrome. Int J Pediatr Otorhinolaryngol 1998;45:113-23.
60. Phelps PD, Coffey RA, Trembath RC, et al. Radiological malformations of the ear in Pendred syndrome. Clin Radiol 1998;53: 268-73.
61. Everett LA, Glaser B, Beck JC, et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 1997;17:411-22.
62. Van Hauwe P, Everett LA, Coucke P, et al. Two frequent missense mutations in Pendred syndrome. Hum Molec Genet 1998; 7:1099-104.
63. OMIM (Online Mendelian Inheritance in Man) Website from National Center for Biotechnology Information. URL: http:// www.ncbi.nlm.nih.gov/htbin-post/Omim
64. Scott DA, Wang R, Kreman TM, et al. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet 1999; 21:440-3.
65. Everett LA, Morsli H, Wu DK, et al. Expression pattern of the mouse ortholog of the Pendred's syndrome gene (Pds) suggests a key role for pendrin in the inner ear. Proc Natl Acad Sci USA 1999;96:9727-32.
66. Li XC, Everett LA, Lalwani AK, et al. A mutation in PDS causes non-syndromic recessive deafness. Nat Genet 1998;18:215-7.
67. Greinwald JH Jr, Wayne S, Chen AH, et al. Localization of a novel gene for nonsyndromic hearing loss (DFNB 17) to chromosome region 7q31. Am J Med Genet 1998;78:107-13.
68. Usami S, Abe S, Weston MD, et al. Non-syndromic hearing loss associated with enlarged vestibular aqueduct is caused by PDS mutations. Hum Genet 1999;104:188-92.
69. Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927;1:501-6.
70. Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998;9:1736-50.
71. Yoshikawa N, White RHR, Cameron AH. Familial hematuria: clinico-pathological correlations. Clin Nephrol 1982;17:172-82.
72. Kashtan CE. Alport syndrome: is diagnosis only skin-deep? Kidney Int 1999;55:1575-6.
73. Arnott EJ, Crawfurd MDA, Toghill PJ. Anterior lenticonus and Alport's syndrome. Br J Ophthal 1966;50:390-403.
74. Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248:1224-7.
75. Kalluri R, Shield CF III, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997;99:2470-8.
76. Cosgrove D, Samuelson G, Pinnt J. Immunohistochemical localization of basement membranecollagens and associated proteins in the murine cochlea. Hear Res 1996;97:54-65.
77. Gubler MC, Knebelmann B, Beziau A, et al. Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution. Kidney Int 1995;47:1142-7.
78. Jefferson JA, Lemmink HH, Hughes AE, et al. Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4). Nephrol Dial Transplant 1997;12:1595-9.
79. Baumal R, Thorner P, Valli VEO, et al. Renal disease in carrier female dogs with X-linked hereditary nephritis: implications for female patients with this disease. Am J Pathol 1991;139:751-64.
80. Lees G, Helman RG, Kashtan CE, et al. A new form of X-linked dominant hereditary nephritis in dogs. Am J Vet Res 1999;60: 373-83.
81. Lees GE, Wilson PD, Helman RG, et al. Glomerular ultrastructural changes similar to hereditary nephritis in 4 English cocker spaniel dogs. J Vet Int Med 1997;11:80-5.
82. Melnick M, Bixler D, Nance WE, et al. Familial branchio-otorenal dysplasia: a new addition to the branchial arch syndromes. Clin Genet 1976;9:25-34.
83. Cremers CW, Fikkers-van Noord M. The earpits-deafness syndrome: clinical and genetic aspects. Int J Pediatr Otorhinolaryngol 1980;2:309-22.
84. Fraser FC, Ling D, Clogg D, et al. Genetic aspects of the BOR syndrome: branchial fistulas, ear pits, hearing loss, and renal anomalies. Am J Med Genet 1978;2:241-52.
85. Fraser FC, Sproule JR, Halal F. Frequency of the branchio-otorenal (BOR) syndrome in children with profound hearing loss. Am J Med Genet 1980;7:341-9.
86. Abdelhak S, Kalatzis V, Heilig R, et al. A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. Nat Genet 1997;2:157-64.
87. Kumar S, Deffenbacher K, Cremers CW, et al. Branchio-otorenal syndrome: identification of novel mutations, molecular characterization, mutation distribution, and prospects for genetic testing. Genet Test 1997-8;1:243-51.
88. Abdelhak S, Kalatzis V, Heilig R, et al. Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (eyaHR) of EYA1. Hum Molec Genet 1997;13:2247-55.
89. Xu PX, Adams J, Peters H, et al. Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet 1999;23:113-7.
90. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1956;54:59-68.
91. Pernot C, Henry M, Debruille C. Cardio-auditory syndromes of genetic origin. Coeur Med Interne 1974;13:429-43.
92. Ocal B, Imamoglu A, Atalay S, et al. Prevalence of idiopathic long QT syndrome in children with congenital deafness. Pediatr Cardiol 1997;18:401-5.
93. Neyroud N, Tesson F, Denjoy I, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nature Genet 1997;15:186-9.
94. Splawski I, Timothy KW, Vincent GM, et al. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med 1997;336:1562-7.
95. Schulze-Bahr E, Wang Q, Wedekind H, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 1997;17: 267-8.
96. Ackerman MJ, Tester DJ, Porter CJ, et al. Molecular diagnosis of the inherited long-QT syndrome in a woman who died after neardrowning. N Engl J Med 1999;341:1121-5.
97. NIH Consensus Development Conference. Neurofibromatosis: conference statement. Arch Neurol 1988;45:475-578.
98. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom: I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
99. Trofatter JA, MacCollin M, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
100. Rouleau GA, Mercel P, Lutchman M, et al. Alteration in a new gene encoding a putative member-organizing protein causes neurofibromatosis type 2, Nature 1993;363:515-21.
101. Gusella JF, Ramesh V, MacCollin M, et al. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1999; 1423:M29-36.
102. Kluwe L, Mautner VF. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 1996;97:224-7.
103. Evans DGR, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5.
104. Crouzon O. Dysostose cranio-faciale hereditaire. Bull Mem Soc Med Hop Paris 1912;33:545-55.
105. Cohen MM, Kreiborg S. Birth prevalence studies of the Crouzon syndrome: comparison of direct and indirect methods. Clin Genet 1992;41:12-5.
106. Orvidas LJ, Fabry LB, Diacova S, et al. Hearing and otopathology in Crouzon syndrome. Laryngoscope 1999;109:1372-5.
107. Hollway GE, Suthers GK, Haan EA, et al. Mutation detection in FGFR2 craniosynostosis syndromes. Hum Genet 1997;99:251-5.
108. Sakaguchi K, Lorenzi MV, Bottaro DP, et al. The acidic domain and first immunoglobulin-like loop of fibroblast growth factor receptor 2 modulate downstream signaling through glycosaminoglycan modification. Molec Cell Biol 1999;19:6754-64.
109. Reardon W, Winter RM, Rutland P, et al. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994;8:98-103.
110. Steinberger D, Vriend G, Mulliken JB, et al. The mutations in FGFR2-associated craniosynostoses are clustered in five structural elements of immunoglobulin-like domain III of the receptor. Hum Genet 1998;102:145-50.
111. Norrie G. Causes of blindness in children: twenty-five years' experience of Danish institutes for the blind. Acta Ophthalmol (Copenh) 1927;5:257-86.
112. Berger W, Meindl A, van de Pol TJR, et al. Isolation of a candidate gene for Norrie disease by positional cloning. Nat Genet 1992;1:199-203.
113. Nadol JB Jr, Eavey RD, Liberfarb RM, et al. Histopathology of the ears, eyes, and brain in Norrie's disease (oculoacousticocerebral degeneration). Am J Otolaryngol 1990;11:112-24.
114. Lindsay S, Thiselton DL, Bateman JB, et al. Localisation of the gene for Norrie disease to between DXS7 and DXS426 on Xp. Hum Genet 1992;88:349-50.
115. Sims KB, Lebo RV, Benson G, et al. The Norrie disease gene maps to a 150 kb region on chromosome Xp11.3. Hum Molec Genet 1992;1:83-9.
116. Chen ZY, Hendriks RW, Jobling MA, et al. Isolation and characterization of a candidate gene for Norrie disease. Nature Genet 1992;1:204-8.
117. Perez-Vilar J, Hill RL. The carboxyl-terminal 90 residues of porcine submaxillary mucin are sufficient for forming disulfidebonded dimers. J Biol Chem 1998;273:6982-8.
118. Meitinger T, Meindl A, Bork P, et al. Molecular modelling of the Norrie disease protein predicts a cystine knot growth factor tertiary structure. Nat Genet 1993;5:376-80.
119. Hartzer MK, Cheng M, Liu X, et al. Localization of the Norrie disease gene mRNA by in situ hybridization. Brain Res Bull 1999;49:355-8.
120. Treacher Collins E. Case with symmetrical congenital notches in the outer part of each lower lid and defective development of the malar bones. Trans Ophthalmol Soc UK 1900;20:190-2.
121. Franceschetti PA, Zwahlen P. Un syndrome nouveau: la dysostose mandibulofaciale. Bull Schweiz Akad Med Wiss 1944;1: 60-6.
122. Jahrsdoerfer RA, Jacobson JT. Treacher Collins syndrome: otologic and auditory management. J Am Acad Audiol 1995;6:93-102.
123. Herring SW, Rowlatt UF, Pruzansky S. Anatomical abnormalities in mandibulofacial dysostosis. Am J Med Genet 1979;3:225-9.
124. Dixon MN, Dixon J, Houseal T, et al. Narrowing the position of the Treacher Collins syndrome locus to a small interval between three new microsatellite markers at 5q32-33.1. Am J Hum Genet 1993;52:907-14.
125. Treacher Collins Syndrome Collaborative Group. Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. Nature Genet 1996;12:130-6.
126. Edwards SJ, Gladwin AJ, Dixon MJ. The mutational spectrum in Treacher Collins syndrome reveals a predominance of mutations that create a premature-termination codon. Am J Hum Genet 1997;60:515-24.
127. Dixon J, Hovanes K, Shiang R, et al. Sequence analysis, identification of evolutionary conserved motifs and expression analysis of murine tcof1 provide further evidence for a potential function for the gene and its human homologue, TCOF1. Hum Molec Genet 1997;6:727-37.
128. Wise CA, Chiang LC, Paznekas WA, et al. TCOF1 gene encodes a putative nucleolar phosphoprotein that exhibits mutations in Treacher Collins syndrome throughout its coding region. Proc Natl Acad Sci 1997;94:3110-5.
129. Marsh KL, Dixon J, Dixon MJ. Mutations in the Treacher Collins syndrome gene lead to mislocalization of the nucleolar protein treacle. Hum Molec Genet 1998;7:1795-800.
130. Wareing M, Mhatre AN, Pettis R, et al. Cationic liposome mediated transgene expression in the guinea pig cochlea. Hear Res 1999;128:61-9.
131. Carvalho GJ, Lalwani AK. The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. Am J Otol 1999;20:87-90.
132. Lalwani AK, Walsh BJ, Carvalho GJ, et al. Expression of adenoassociated virus integrated transgene within the mammalian vestibular organs. Am J Otol 1998;19:390-5.
133. Lalwani AK, Han JJ, Walsh BJ, et al. Green fluorescent protein as a reporter for gene transfer studies in the cochlea. Hear Res 1997;114:139-47.
134. Lalwani AK, Walsh BJ, Reilly PG, et al. Development of in vivo gene therapy for hearing disorders: introduction of adenoassociated virus into the cochlea of the guinea pig. Gene Ther 1996;3:588-92.
135. Fogelman I, Maisey MN, Clarke SEM. An Atlas of Clinical Nuclear Medicine. St. Louis: CV Mosby, 1994.
136. Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994;8:77-81.
137. Galvin BD, Hart KC, Meyer AN, et al. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. Proc Natl Acad Sci USA 1996;93:7894-9.
138. Jin H, May M, Tranebjaerg L, et al. A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet 1996;14:177-80.
139. Tyson J, Tranebjaerg L, Bellman S, et al. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum Molec Genet 1997;6:2179-85.
140. Williams CJ, Ganguly A, Considine E, et al. A-2→G transition at the 3′ acceptor splice site of IVS17 characterizes the COL2A1 gene mutation in the original Stickler syndrome kindred. Am J Med Genet 1996;63:461-7.
141. Vikkula M, Mariman EC, Lui VC, et al. Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus. Cell 1995;80:431-7.
142. Richards AJ, Yates JR, Williams R, et al. A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. Hum Molec Genet 1996;5:1339-43.
143. Kaplan J, Gerber S, Bonneau D, et al. A gene for Usher syndrome type 1 (USH1A) maps to chromosome 14q. Genomics 1992;14: 979-87.
144. Smith RJ, Coppage KB, Ankerstjerne JK, et al. Localization of the gene for branchiootorenal syndrome to chromosome 8q. Genomics 1992;14:841-4.
145. Wayne S, Der Kaloustian VM, Schloss M, et al. Localization of the Usher syndrome type ID gene (Ush1D) to chromosome 10. Hum Molec Genet 1996;5:1689-92.
146. Chaib H, Kaplan J, Gerber S, et al. A newly identified locus for Usher syndrome type I, USH1E, maps to chromosome 21q21. Hum Molec Genet 1997;6:27-31.